Faeth Therapeutics to Present PIKTOR Preclinical Breast Cancer Data at ESMO 2026

• Faeth Therapeutics will present preclinical PIKTOR breast cancer data at ESMO in Madrid on October 23, 2026.
• PIKTOR suppressed key cancer-signaling targets in preclinical models, matching or exceeding the activity of tested single-node inhibitors.
• The presentation evaluates PIKTOR alone and with endocrine therapies or CDK inhibitors, including head-to-head comparisons with gedatolisib in breast cancer models.
• The findings are intended to inform the ongoing FTH-PIK-101 Phase 1b/2 trial in HR+/HER2- breast cancer.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Faeth Therapeutics Inc published the original content used to generate this news brief via Business Wire (Ref. ID: 202610190730BIZWIRE_USPR_____20261019_BW736343) on October 19, 2026, and is solely responsible for the information contained therein.